Arvinas (ARVN) 2024 Wells Fargo Healthcare Conference summary

Pipeline overview and lead program updates

• Lead program vepdegestrant, partnered with Pfizer, is positioned as a potential backbone therapy for metastatic breast cancer, with pivotal VERITAC-2 trial data expected in late 2024 or early 2025.

• Plans for second-line and first-line combination trials with vepdegestrant are set for 2025, aiming for broad combinability with other cancer therapies.

• The pipeline includes neuroscience and hematology assets, with ARV-102 (LRRK2 degrader) in phase 1 and ARV-393 (BCL6 degrader) also in early clinical development.

• ARV-766 for prostate cancer was recently outlicensed to Novartis, expanding its reach.

Competitive landscape and efficacy expectations

• The positive readout of Lilly's EMBER-3 trial is seen as raising the efficacy bar for ER-targeting therapies, but differences in trial design make direct comparisons complex.

• Vepdegestrant is expected to perform well, especially in ESR1 mutant populations, with efficacy in wild type expected to be lower but still present.

• Combination regimens are anticipated to outperform monotherapy, with safety profiles playing a key role in clinical adoption.

• Real-world use may see off-label combinations, as seen with other agents, due to physician comfort with managing side effects.

Drug-drug interaction (DDI) and combination studies

• Vepdegestrant is classified as a weak CYP3A4 inhibitor, with DDI studies showing minimal clinically relevant impact on most combination partners except palbociclib, where neutropenia rates are higher.

• Ongoing and upcoming studies with abemaciclib and ribociclib are expected to confirm safe combinability, with data readouts anticipated within the next six months.

• Dose adjustments and standard clinical management strategies are in place to address neutropenia risks.